Efficacy and Safety of Once-Weekly Semaglutide Versus Exenatide ER in Subjects With Type 2 Diabetes (SUSTAIN 3): A 56-Week, Open-Label, Randomized Clinical Trial

Andrew Ahmann, Vanita R. Aroda, G. Charpentier et al.|Diabetes Care|2017

Cited by 574